Le SIDA en Afrique subsaharienne (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development

Identifieur interne : 000036 ( Istex/Corpus ); précédent : 000035; suivant : 000037

Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development

Auteurs : Jes Dietrich ; T. Mark Doherty

Source :

RBID : ISTEX:01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67

English descriptors

Abstract

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with M. tuberculosis. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti‐mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.

Url:
DOI: 10.1111/j.1600-0463.2009.02458.x

Links to Exploration step

ISTEX:01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development</title>
<author>
<name sortKey="Dietrich, Jes" sort="Dietrich, Jes" uniqKey="Dietrich J" first="Jes" last="Dietrich">Jes Dietrich</name>
<affiliation>
<mods:affiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Doherty, T Mark" sort="Doherty, T Mark" uniqKey="Doherty T" first="T. Mark" last="Doherty">T. Mark Doherty</name>
<affiliation>
<mods:affiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1111/j.1600-0463.2009.02458.x</idno>
<idno type="url">https://api.istex.fr/document/01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000036</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000036</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Interaction of
<hi rend="italic">Mycobacterium tuberculosis</hi>
with the host: consequences for vaccine development</title>
<author>
<name sortKey="Dietrich, Jes" sort="Dietrich, Jes" uniqKey="Dietrich J" first="Jes" last="Dietrich">Jes Dietrich</name>
<affiliation>
<mods:affiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Doherty, T Mark" sort="Doherty, T Mark" uniqKey="Doherty T" first="T. Mark" last="Doherty">T. Mark Doherty</name>
<affiliation>
<mods:affiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">APMIS</title>
<title level="j" type="alt">APMIS</title>
<idno type="ISSN">0903-4641</idno>
<idno type="eISSN">1600-0463</idno>
<imprint>
<biblScope unit="vol">117</biblScope>
<biblScope unit="issue">5‐6</biblScope>
<biblScope unit="page" from="440">440</biblScope>
<biblScope unit="page" to="457">457</biblScope>
<biblScope unit="page-count">18</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2009-05">2009-05</date>
</imprint>
<idno type="ISSN">0903-4641</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0903-4641</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Active tuberculosis</term>
<term>Acute infection</term>
<term>Adaptive</term>
<term>Adaptive immunity</term>
<term>Andersen</term>
<term>Animal models</term>
<term>Antigen presentation</term>
<term>Antigen processing</term>
<term>Antigenic repertoire</term>
<term>Apmis</term>
<term>Apmis interaction</term>
<term>Apoptosis</term>
<term>Authors journal compilation</term>
<term>Avirulent mycobacteria</term>
<term>Bacteria</term>
<term>Bacterial antigens</term>
<term>Bacterial growth</term>
<term>Bacterial replication</term>
<term>Bacterium</term>
<term>Booster vaccine</term>
<term>Bovis</term>
<term>Causative agent</term>
<term>Cd4t cells</term>
<term>Cd8t cells</term>
<term>Cell death</term>
<term>Cell microbiol</term>
<term>Cell wall</term>
<term>Cellular level</term>
<term>Chan</term>
<term>Chronic tuberculosis</term>
<term>Clin</term>
<term>Clin immunol</term>
<term>Clin microbiol</term>
<term>Clinical strains</term>
<term>Clinical trials</term>
<term>Complex strategies</term>
<term>Cord factor</term>
<term>Correct response</term>
<term>Curr</term>
<term>Cytokine</term>
<term>Cytokine production</term>
<term>Decoy proteins</term>
<term>Dendritic</term>
<term>Dendritic cells</term>
<term>Dietrich doherty</term>
<term>Different stages</term>
<term>Doherty</term>
<term>Dormancy</term>
<term>Dormant bacteria</term>
<term>Dosr genes</term>
<term>Dosr regulon</term>
<term>Early phase</term>
<term>Early phases</term>
<term>Edinburgh</term>
<term>Effective vaccine</term>
<term>Environmental mycobacteria</term>
<term>Gene expression</term>
<term>Granuloma</term>
<term>Host cell</term>
<term>Host resistance</term>
<term>Host response</term>
<term>Host responses</term>
<term>Human monocytes</term>
<term>Human tuberculosis</term>
<term>Hypoxic conditions</term>
<term>Immun</term>
<term>Immune</term>
<term>Immune cells</term>
<term>Immune reconstitution syndrome</term>
<term>Immune response</term>
<term>Immune responses</term>
<term>Immune system</term>
<term>Immunol</term>
<term>Immunol lett</term>
<term>Infection</term>
<term>Infectious disease immunology</term>
<term>Interferon</term>
<term>Interferon gamma</term>
<term>Intracellular</term>
<term>Intracellular pathogens</term>
<term>Latent infection</term>
<term>Latent stage</term>
<term>Latent tuberculosis</term>
<term>Lipid</term>
<term>Lipoprotein</term>
<term>Long periods</term>
<term>Macrophage</term>
<term>Many years</term>
<term>Maturation</term>
<term>Microarray analysis</term>
<term>Microbiol</term>
<term>Microbiol immunol</term>
<term>Murine</term>
<term>Murine macrophages</term>
<term>Mycobacteria</term>
<term>Mycobacterial</term>
<term>Mycobacterial infection</term>
<term>Mycobacterial lipoprotein</term>
<term>Mycobacterium</term>
<term>Mycobacterium bovis</term>
<term>Mycobacterium tuberculosis</term>
<term>Mycobacterium tuberculosis infection</term>
<term>Necrosis</term>
<term>Nitric</term>
<term>Nitric oxide</term>
<term>Pathogen</term>
<term>Phagosome</term>
<term>Phagosome maturation</term>
<term>Protective immunity</term>
<term>Protein expression</term>
<term>Pulmonary tuberculosis</term>
<term>Ratio increases</term>
<term>Reactivation</term>
<term>Recent work</term>
<term>Receptor</term>
<term>Replication</term>
<term>Same time</term>
<term>Statens serum institute</term>
<term>Subunit</term>
<term>Subunit vaccine</term>
<term>Subunit vaccines</term>
<term>Tissue destruction</term>
<term>Transcriptional responses</term>
<term>Trehalose dimycolate</term>
<term>Trends microbiol</term>
<term>Tuberc lung</term>
<term>Tuberculosis</term>
<term>Tuberculosis infection</term>
<term>Tuberculosis interference</term>
<term>Tuberculosis patients</term>
<term>Tumor necrosis</term>
<term>Tumor necrosis factor</term>
<term>Unpublished data</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Vaccine design</term>
<term>Vaccine development</term>
<term>Vaccine strategies</term>
<term>Vaccine strategy</term>
<term>Virulence</term>
<term>World health organization</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Active tuberculosis</term>
<term>Acute infection</term>
<term>Adaptive</term>
<term>Adaptive immunity</term>
<term>Andersen</term>
<term>Animal models</term>
<term>Antigen presentation</term>
<term>Antigen processing</term>
<term>Antigenic repertoire</term>
<term>Apmis</term>
<term>Apmis interaction</term>
<term>Apoptosis</term>
<term>Authors journal compilation</term>
<term>Avirulent mycobacteria</term>
<term>Bacteria</term>
<term>Bacterial antigens</term>
<term>Bacterial growth</term>
<term>Bacterial replication</term>
<term>Bacterium</term>
<term>Booster vaccine</term>
<term>Bovis</term>
<term>Causative agent</term>
<term>Cd4t cells</term>
<term>Cd8t cells</term>
<term>Cell death</term>
<term>Cell microbiol</term>
<term>Cell wall</term>
<term>Cellular level</term>
<term>Chan</term>
<term>Chronic tuberculosis</term>
<term>Clin</term>
<term>Clin immunol</term>
<term>Clin microbiol</term>
<term>Clinical strains</term>
<term>Clinical trials</term>
<term>Complex strategies</term>
<term>Cord factor</term>
<term>Correct response</term>
<term>Curr</term>
<term>Cytokine</term>
<term>Cytokine production</term>
<term>Decoy proteins</term>
<term>Dendritic</term>
<term>Dendritic cells</term>
<term>Dietrich doherty</term>
<term>Different stages</term>
<term>Doherty</term>
<term>Dormancy</term>
<term>Dormant bacteria</term>
<term>Dosr genes</term>
<term>Dosr regulon</term>
<term>Early phase</term>
<term>Early phases</term>
<term>Edinburgh</term>
<term>Effective vaccine</term>
<term>Environmental mycobacteria</term>
<term>Gene expression</term>
<term>Granuloma</term>
<term>Host cell</term>
<term>Host resistance</term>
<term>Host response</term>
<term>Host responses</term>
<term>Human monocytes</term>
<term>Human tuberculosis</term>
<term>Hypoxic conditions</term>
<term>Immun</term>
<term>Immune</term>
<term>Immune cells</term>
<term>Immune reconstitution syndrome</term>
<term>Immune response</term>
<term>Immune responses</term>
<term>Immune system</term>
<term>Immunol</term>
<term>Immunol lett</term>
<term>Infection</term>
<term>Infectious disease immunology</term>
<term>Interferon</term>
<term>Interferon gamma</term>
<term>Intracellular</term>
<term>Intracellular pathogens</term>
<term>Latent infection</term>
<term>Latent stage</term>
<term>Latent tuberculosis</term>
<term>Lipid</term>
<term>Lipoprotein</term>
<term>Long periods</term>
<term>Macrophage</term>
<term>Many years</term>
<term>Maturation</term>
<term>Microarray analysis</term>
<term>Microbiol</term>
<term>Microbiol immunol</term>
<term>Murine</term>
<term>Murine macrophages</term>
<term>Mycobacteria</term>
<term>Mycobacterial</term>
<term>Mycobacterial infection</term>
<term>Mycobacterial lipoprotein</term>
<term>Mycobacterium</term>
<term>Mycobacterium bovis</term>
<term>Mycobacterium tuberculosis</term>
<term>Mycobacterium tuberculosis infection</term>
<term>Necrosis</term>
<term>Nitric</term>
<term>Nitric oxide</term>
<term>Pathogen</term>
<term>Phagosome</term>
<term>Phagosome maturation</term>
<term>Protective immunity</term>
<term>Protein expression</term>
<term>Pulmonary tuberculosis</term>
<term>Ratio increases</term>
<term>Reactivation</term>
<term>Recent work</term>
<term>Receptor</term>
<term>Replication</term>
<term>Same time</term>
<term>Statens serum institute</term>
<term>Subunit</term>
<term>Subunit vaccine</term>
<term>Subunit vaccines</term>
<term>Tissue destruction</term>
<term>Transcriptional responses</term>
<term>Trehalose dimycolate</term>
<term>Trends microbiol</term>
<term>Tuberc lung</term>
<term>Tuberculosis</term>
<term>Tuberculosis infection</term>
<term>Tuberculosis interference</term>
<term>Tuberculosis patients</term>
<term>Tumor necrosis</term>
<term>Tumor necrosis factor</term>
<term>Unpublished data</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Vaccine design</term>
<term>Vaccine development</term>
<term>Vaccine strategies</term>
<term>Vaccine strategy</term>
<term>Virulence</term>
<term>World health organization</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with M. tuberculosis. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti‐mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.</div>
</front>
</TEI>
<istex>
<corpusName>wiley</corpusName>
<keywords>
<teeft>
<json:string>mycobacterium</json:string>
<json:string>immune</json:string>
<json:string>immunol</json:string>
<json:string>vaccine</json:string>
<json:string>mycobacterium tuberculosis</json:string>
<json:string>macrophage</json:string>
<json:string>immune response</json:string>
<json:string>apoptosis</json:string>
<json:string>microbiol</json:string>
<json:string>receptor</json:string>
<json:string>apmis</json:string>
<json:string>pathogen</json:string>
<json:string>tuberculosis</json:string>
<json:string>immun</json:string>
<json:string>authors journal compilation</json:string>
<json:string>mycobacterial</json:string>
<json:string>phagosome</json:string>
<json:string>doherty</json:string>
<json:string>granuloma</json:string>
<json:string>cytokine</json:string>
<json:string>tuberculosis infection</json:string>
<json:string>murine</json:string>
<json:string>intracellular</json:string>
<json:string>clin</json:string>
<json:string>subunit</json:string>
<json:string>lipoprotein</json:string>
<json:string>dendritic</json:string>
<json:string>adaptive</json:string>
<json:string>mycobacteria</json:string>
<json:string>edinburgh</json:string>
<json:string>mycobacterium tuberculosis infection</json:string>
<json:string>interferon</json:string>
<json:string>dormancy</json:string>
<json:string>apmis interaction</json:string>
<json:string>curr</json:string>
<json:string>immune responses</json:string>
<json:string>chan</json:string>
<json:string>dietrich doherty</json:string>
<json:string>bacterium</json:string>
<json:string>reactivation</json:string>
<json:string>animal models</json:string>
<json:string>bovis</json:string>
<json:string>latent infection</json:string>
<json:string>lipid</json:string>
<json:string>nitric</json:string>
<json:string>phagosome maturation</json:string>
<json:string>antigen presentation</json:string>
<json:string>tissue destruction</json:string>
<json:string>subunit vaccines</json:string>
<json:string>immune system</json:string>
<json:string>nitric oxide</json:string>
<json:string>gene expression</json:string>
<json:string>infection</json:string>
<json:string>protective immunity</json:string>
<json:string>cell microbiol</json:string>
<json:string>murine macrophages</json:string>
<json:string>dendritic cells</json:string>
<json:string>cell death</json:string>
<json:string>vaccination</json:string>
<json:string>replication</json:string>
<json:string>andersen</json:string>
<json:string>adaptive immunity</json:string>
<json:string>cytokine production</json:string>
<json:string>microbiol immunol</json:string>
<json:string>mycobacterial infection</json:string>
<json:string>clinical trials</json:string>
<json:string>vaccine development</json:string>
<json:string>booster vaccine</json:string>
<json:string>bacterial replication</json:string>
<json:string>transcriptional responses</json:string>
<json:string>cell wall</json:string>
<json:string>environmental mycobacteria</json:string>
<json:string>tumor necrosis factor</json:string>
<json:string>tuberc lung</json:string>
<json:string>latent tuberculosis</json:string>
<json:string>pulmonary tuberculosis</json:string>
<json:string>avirulent mycobacteria</json:string>
<json:string>necrosis</json:string>
<json:string>virulence</json:string>
<json:string>maturation</json:string>
<json:string>bacteria</json:string>
<json:string>effective vaccine</json:string>
<json:string>unpublished data</json:string>
<json:string>cellular level</json:string>
<json:string>recent work</json:string>
<json:string>human monocytes</json:string>
<json:string>correct response</json:string>
<json:string>long periods</json:string>
<json:string>bacterial growth</json:string>
<json:string>early phase</json:string>
<json:string>same time</json:string>
<json:string>many years</json:string>
<json:string>antigenic repertoire</json:string>
<json:string>host responses</json:string>
<json:string>bacterial antigens</json:string>
<json:string>tuberculosis interference</json:string>
<json:string>different stages</json:string>
<json:string>vaccine strategies</json:string>
<json:string>immune cells</json:string>
<json:string>hypoxic conditions</json:string>
<json:string>dosr regulon</json:string>
<json:string>dosr genes</json:string>
<json:string>microarray analysis</json:string>
<json:string>trehalose dimycolate</json:string>
<json:string>host response</json:string>
<json:string>chronic tuberculosis</json:string>
<json:string>protein expression</json:string>
<json:string>decoy proteins</json:string>
<json:string>subunit vaccine</json:string>
<json:string>world health organization</json:string>
<json:string>immune reconstitution syndrome</json:string>
<json:string>vaccine design</json:string>
<json:string>vaccine strategy</json:string>
<json:string>complex strategies</json:string>
<json:string>host cell</json:string>
<json:string>mycobacterium bovis</json:string>
<json:string>causative agent</json:string>
<json:string>statens serum institute</json:string>
<json:string>trends microbiol</json:string>
<json:string>infectious disease immunology</json:string>
<json:string>clin microbiol</json:string>
<json:string>clinical strains</json:string>
<json:string>early phases</json:string>
<json:string>tuberculosis patients</json:string>
<json:string>intracellular pathogens</json:string>
<json:string>cd4t cells</json:string>
<json:string>cd8t cells</json:string>
<json:string>cord factor</json:string>
<json:string>acute infection</json:string>
<json:string>antigen processing</json:string>
<json:string>ratio increases</json:string>
<json:string>immunol lett</json:string>
<json:string>mycobacterial lipoprotein</json:string>
<json:string>host resistance</json:string>
<json:string>interferon gamma</json:string>
<json:string>latent stage</json:string>
<json:string>active tuberculosis</json:string>
<json:string>tumor necrosis</json:string>
<json:string>human tuberculosis</json:string>
<json:string>clin immunol</json:string>
<json:string>dormant bacteria</json:string>
</teeft>
</keywords>
<author>
<json:item>
<name>JES DIETRICH</name>
<affiliations>
<json:string>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</json:string>
</affiliations>
</json:item>
<json:item>
<name>T. MARK DOHERTY</name>
<affiliations>
<json:string>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</json:string>
</affiliations>
</json:item>
</author>
<subject>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>Tuberculosis</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>bacterial</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>vaccination</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>BCG</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>latency</value>
</json:item>
</subject>
<articleId>
<json:string>APM2458</json:string>
</articleId>
<language>
<json:string>eng</json:string>
</language>
<originalGenre>
<json:string>article</json:string>
</originalGenre>
<abstract>Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with M. tuberculosis. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti‐mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.</abstract>
<qualityIndicators>
<score>6.404</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>595.276 x 782.362 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>760</abstractCharCount>
<pdfWordCount>10183</pdfWordCount>
<pdfCharCount>66499</pdfCharCount>
<pdfPageCount>18</pdfPageCount>
<abstractWordCount>117</abstractWordCount>
</qualityIndicators>
<title>Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development</title>
<genre>
<json:string>article</json:string>
</genre>
<host>
<title>APMIS</title>
<language>
<json:string>unknown</json:string>
</language>
<doi>
<json:string>10.1111/(ISSN)1600-0463</json:string>
</doi>
<issn>
<json:string>0903-4641</json:string>
</issn>
<eissn>
<json:string>1600-0463</json:string>
</eissn>
<publisherId>
<json:string>APM</json:string>
</publisherId>
<volume>117</volume>
<issue>5‐6</issue>
<pages>
<first>440</first>
<last>457</last>
<total>18</total>
</pages>
<genre>
<json:string>journal</json:string>
</genre>
</host>
<categories>
<wos>
<json:string>science</json:string>
<json:string>pathology</json:string>
<json:string>microbiology</json:string>
<json:string>immunology</json:string>
</wos>
<scienceMetrix>
<json:string>health sciences</json:string>
<json:string>clinical medicine</json:string>
<json:string>oncology & carcinogenesis</json:string>
</scienceMetrix>
<inist>
<json:string>sciences appliquees, technologies et medecines</json:string>
<json:string>sciences biologiques et medicales</json:string>
<json:string>sciences medicales</json:string>
</inist>
</categories>
<publicationDate>2009</publicationDate>
<copyrightDate>2009</copyrightDate>
<doi>
<json:string>10.1111/j.1600-0463.2009.02458.x</json:string>
</doi>
<id>01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67</id>
<score>1</score>
<fulltext>
<json:item>
<extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67/fulltext/pdf</uri>
</json:item>
<json:item>
<extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67/fulltext/tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main">Interaction of
<hi rend="italic">Mycobacterium tuberculosis</hi>
with the host: consequences for vaccine development</title>
</titleStmt>
<publicationStmt>
<authority>ISTEX</authority>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<availability>
<licence>© 2009 The Authors. Journal Compilation © 2009 APMIS</licence>
</availability>
<date type="published" when="2009-05"></date>
</publicationStmt>
<notesStmt>
<note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc>
<biblStruct type="article">
<analytic>
<title level="a" type="main">Interaction of
<hi rend="italic">Mycobacterium tuberculosis</hi>
with the host: consequences for vaccine development</title>
<title level="a" type="short">INTERACTION OF M. TUBERCULOSIS WITH THE HOST</title>
<author xml:id="author-0000">
<persName>
<forename type="first">JES</forename>
<surname>DIETRICH</surname>
</persName>
<affiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
<address>
<country key="DK"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0001">
<persName>
<forename type="first">T. MARK</forename>
<surname>DOHERTY</surname>
</persName>
<affiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
<address>
<country key="DK"></country>
</address>
</affiliation>
</author>
<idno type="istex">01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67</idno>
<idno type="ark">ark:/67375/WNG-HD8X42JJ-C</idno>
<idno type="DOI">10.1111/j.1600-0463.2009.02458.x</idno>
<idno type="unit">APM2458</idno>
<idno type="supplier">2458</idno>
<idno type="toTypesetVersion">file:APM.APM2458.pdf</idno>
</analytic>
<monogr>
<title level="j" type="main">APMIS</title>
<title level="j" type="alt">APMIS</title>
<idno type="pISSN">0903-4641</idno>
<idno type="eISSN">1600-0463</idno>
<idno type="book-DOI">10.1111/(ISSN)1600-0463</idno>
<idno type="book-part-DOI">10.1111/apm.2009.117.issue-5-6</idno>
<idno type="product">APM</idno>
<idno type="publisherDivision">ST</idno>
<imprint>
<biblScope unit="vol">117</biblScope>
<biblScope unit="issue">5‐6</biblScope>
<biblScope unit="page" from="440">440</biblScope>
<biblScope unit="page" to="457">457</biblScope>
<biblScope unit="page-count">18</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2009-05"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<abstract xml:lang="en" style="main">
<p>
<hi rend="italic">Mycobacterium tuberculosis</hi>
, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with
<hi rend="italic">M. tuberculosis</hi>
. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti‐mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of
<hi rend="italic">M. tuberculosis</hi>
with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.</p>
</abstract>
<textClass>
<keywords xml:lang="en">
<term xml:id="k1">Tuberculosis</term>
<term xml:id="k2">bacterial</term>
<term xml:id="k3">vaccination</term>
<term xml:id="k4">BCG</term>
<term xml:id="k5">latency</term>
</keywords>
<keywords rend="tocHeading1">
<term>Review Articles</term>
</keywords>
</textClass>
<langUsage>
<language ident="en"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="Wiley, elements deleted: body">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document>
<component version="2.0" type="serialArticle" xml:lang="en">
<header>
<publicationMeta level="product">
<publisherInfo>
<publisherName>Blackwell Publishing Ltd</publisherName>
<publisherLoc>Oxford, UK</publisherLoc>
</publisherInfo>
<doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0463</doi>
<issn type="print">0903-4641</issn>
<issn type="electronic">1600-0463</issn>
<idGroup>
<id type="product" value="APM"></id>
<id type="publisherDivision" value="ST"></id>
</idGroup>
<titleGroup>
<title type="main" sort="APMIS">APMIS</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="05005">
<doi origin="wiley">10.1111/apm.2009.117.issue-5-6</doi>
<numberingGroup>
<numbering type="journalVolume" number="117">117</numbering>
<numbering type="journalIssue">5‐6</numbering>
</numberingGroup>
<coverDate startDate="2009-05">May/June 2009</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="10" status="forIssue">
<doi origin="wiley">10.1111/j.1600-0463.2009.02458.x</doi>
<idGroup>
<id type="unit" value="APM2458"></id>
<id type="supplier" value="2458"></id>
</idGroup>
<countGroup>
<count type="pageTotal" number="18"></count>
</countGroup>
<titleGroup>
<title type="tocHeading1">Review Articles</title>
</titleGroup>
<copyright>© 2009 The Authors. Journal Compilation © 2009 APMIS</copyright>
<eventGroup>
<event type="firstOnline" date="2009-04-21"></event>
<event type="publishedOnlineFinalForm" date="2009-04-21"></event>
<event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-15"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event>
</eventGroup>
<numberingGroup>
<numbering type="pageFirst" number="440">440</numbering>
<numbering type="pageLast" number="457">457</numbering>
</numberingGroup>
<correspondenceTo>Jes Dietrich, Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, DK‐2300 Copenhagen, Denmark. e‐mail:
<email normalForm="JDI@ssi.dk">JDI@ssi.dk</email>
</correspondenceTo>
<linkGroup>
<link type="toTypesetVersion" href="file:APM.APM2458.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta>
<unparsedEditorialHistory>Invited review</unparsedEditorialHistory>
<countGroup>
<count type="figureTotal" number="2"></count>
<count type="tableTotal" number="0"></count>
<count type="formulaTotal" number="0"></count>
<count type="referenceTotal" number="166"></count>
<count type="wordTotal" number="13720"></count>
<count type="linksCrossRef" number="116"></count>
</countGroup>
<titleGroup>
<title type="main">Interaction of
<i>Mycobacterium tuberculosis</i>
with the host: consequences for vaccine development</title>
<title type="shortAuthors">DIETRICH & DOHERTY</title>
<title type="short">INTERACTION OF
<i>M. TUBERCULOSIS</i>
WITH THE HOST</title>
</titleGroup>
<creators>
<creator creatorRole="author" xml:id="cr1" affiliationRef="#a1">
<personName>
<givenNames>JES</givenNames>
<familyName>DIETRICH</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr2" affiliationRef="#a1">
<personName>
<givenNames>T. MARK</givenNames>
<familyName>DOHERTY</familyName>
</personName>
</creator>
</creators>
<affiliationGroup>
<affiliation xml:id="a1" countryCode="DK">
<unparsedAffiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en">
<keyword xml:id="k1">Tuberculosis</keyword>
<keyword xml:id="k2">bacterial</keyword>
<keyword xml:id="k3">vaccination</keyword>
<keyword xml:id="k4">BCG</keyword>
<keyword xml:id="k5">latency</keyword>
</keywordGroup>
<abstractGroup>
<abstract type="main" xml:lang="en"><!--

Dietrich J, Doherty TM. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS 2009; 117: 440–57.

-->
<p>
<i>Mycobacterium tuberculosis</i>
, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with
<i>M. tuberculosis</i>
. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti‐mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of
<i>M. tuberculosis</i>
with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en">
<title>INTERACTION OF M. TUBERCULOSIS WITH THE HOST</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en">
<title>Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development</title>
</titleInfo>
<name type="personal">
<namePart type="given">JES</namePart>
<namePart type="family">DIETRICH</namePart>
<affiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">T. MARK</namePart>
<namePart type="family">DOHERTY</namePart>
<affiliation>Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre>
<originInfo>
<publisher>Blackwell Publishing Ltd</publisher>
<place>
<placeTerm type="text">Oxford, UK</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2009-05</dateIssued>
<edition>Invited review</edition>
<copyrightDate encoding="w3cdtf">2009</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<extent unit="figures">2</extent>
<extent unit="tables">0</extent>
<extent unit="formulas">0</extent>
<extent unit="references">166</extent>
<extent unit="linksCrossRef">116</extent>
<extent unit="words">13720</extent>
</physicalDescription>
<abstract lang="en">Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with M. tuberculosis. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti‐mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.</abstract>
<subject lang="en">
<genre>keywords</genre>
<topic>Tuberculosis</topic>
<topic>bacterial</topic>
<topic>vaccination</topic>
<topic>BCG</topic>
<topic>latency</topic>
</subject>
<relatedItem type="host">
<titleInfo>
<title>APMIS</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0903-4641</identifier>
<identifier type="eISSN">1600-0463</identifier>
<identifier type="DOI">10.1111/(ISSN)1600-0463</identifier>
<identifier type="PublisherID">APM</identifier>
<part>
<date>2009</date>
<detail type="volume">
<caption>vol.</caption>
<number>117</number>
</detail>
<detail type="issue">
<caption>no.</caption>
<number>5‐6</number>
</detail>
<extent unit="pages">
<start>440</start>
<end>457</end>
<total>18</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67</identifier>
<identifier type="ark">ark:/67375/WNG-HD8X42JJ-C</identifier>
<identifier type="DOI">10.1111/j.1600-0463.2009.02458.x</identifier>
<identifier type="ArticleID">APM2458</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© 2009 The Authors. Journal Compilation © 2009 APMIS</accessCondition>
<recordInfo>
<recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>Blackwell Publishing Ltd</recordOrigin>
</recordInfo>
</mods>
<json:item>
<extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/document/01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67/metadata/json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000036 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000036 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:01AD0E6E3B41C6A984C35C7B7661FB557EC3AB67
   |texte=   Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development
}}

Wicri

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024